Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL, Salles GA, Moskowitz AJ, Santoro A, Mehta A, Barr PM, Mehta-Shah N, Collins GP, Ansell SM, Brody JD, Domingo-Domenech E, Johnson NA, Cunningham D, Ferrari S, Lisano JM, Krajewski J, Wen R, Akyol A, Crowe R, Savage KJ.
Zinzani PL, et al. Among authors: moskowitz aj.
Blood Adv. 2024 Mar 26:bloodadvances.2023011030. doi: 10.1182/bloodadvances.2023011030. Online ahead of print.
Blood Adv. 2024.
PMID: 38531062
No abstract available.